About: Osteopontin Fragments with Intact Thrombin-Sensitive Site Circulate in Cervical Cancer Patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Osteopontin Fragments with Intact Thrombin-Sensitive Site Circulate in Cervical Cancer Patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Osteopontin Fragments with Intact Thrombin-Sensitive Site Circulate in Cervical Cancer Patients
Creator	Cheung, Tak-Hong Lim, Pak-Leong Wong, Yick-Fu Yim, So-Fan Wong, Raymond Chung, Tony Leung, Danny Ng, Margaret Tam, Frankie
Source	Medline; PMC
abstract	We investigated whether circulating osteopontin (OPN) could be used as a biomarker for cervical cancer. We employed a monoclonal antibody (mAb 659) specific for the unique and intact thrombin-sensitive site in OPN using an inhibition ELISA. We found significantly higher levels of OPN in 33 cervical cancer patients in both the plasma (mean +/- SD, 612 +/- 106 ng/mL) and serum (424 +/- 121 ng/mL) compared to healthy subjects [409 +/- 56 ng/mL, from 31 plasma samples (P < 0.0001), and 314 +/- 98 ng/mL, from 32 serum samples (P = 0.0002), respectively]. Similar results were obtained when the plasma from a bigger group (147 individuals) of cervical cancer patients (560 +/- 211 ng/mL) were compared with the same plasma samples of the healthy individuals (P = 0.0014). More significantly, the OPN level was highest in stage III-IV disease (614 +/- 210 ng/mL, from 52 individuals; P = 0.0001) and least and non-discriminatory in stage I (473 +/- 110 ng/mL, from 40 individuals; P = 0.5318). No such discrimination was found when a mAb of a different specificity (mAb 446) was used in a similar inhibition ELISA to compare the two groups in the first study; a commercial capture ELISA also failed. The possibility that the target epitope recognized by the antibody probe in these assays was absent from the circulating OPN due to protein truncation was supported by gel fractionation of the OPN found in patients’ plasma: 60–64 kDa fragments were found instead of the presumably full-length OPN (68 kDa) seen in healthy people. How these fragments are generated and what possible role they play in cancer biology remain interesting questions.
has issue date	2016-08-05(xsd:dateTime)
bibo:doi	10.1371/journal.pone.0160412
bibo:pmid	27494141
has license	cc0
sha1sum (hex)	db0b1c57b81cdb3facc4177cf7f6a208eab730b9
schema:url	https://doi.org/10.1371/journal.pone.0160412
resource representing a document's title	Osteopontin Fragments with Intact Thrombin-Sensitive Site Circulate in Cervical Cancer Patients
has PubMed Central identifier	PMC4975440
has PubMed identifier	27494141
schema:publication	PLoS One
resource representing a document's body	covid:db0b1c57b81cdb3facc4177cf7f6a208eab730b9#body_text
is schema:about of	named entity 'cervical cancer' named entity 'compared' named entity 'biology' named entity 'compare' named entity 'samples' named entity 'employed' named entity 'Circulate' named entity 'PLAY' named entity 'GROUP' named entity 'SAMPLES' named entity 'ANTIBODY' named entity 'DIFFERENT' named entity 'THESE' named entity '28473' named entity 'HEALTHY' named entity 'USED' named entity 'ROLE' named entity '210' named entity '446' named entity 'INHIBITION' named entity 'POSSIBILITY' named entity 'KDA' named entity 'MONOCLONAL ANTIBODY' named entity 'LEVEL' named entity 'GROUPS' named entity 'STAGE I' named entity 'HIGHEST' named entity 'PATIENTS' named entity 'SEEN' named entity 'COMMERCIAL' named entity 'GENERATED' named entity 'OSTEOPONTIN' named entity 'FAILED' named entity '28560' named entity 'ELISA' named entity 'DISEASE' named entity 'CANCER BIOLOGY' named entity 'PEOPLE' named entity '28P' named entity 'INTERESTING' named entity 'SITE' named entity 'CIRCULATE' named entity 'INTACT' named entity 'CIRCULATING' named entity 'HOW' named entity 'INVESTIGATED' named entity 'STAGE III' named entity '612' named entity 'DUE TO' named entity 'COMPARED' named entity '28424' named entity 'TARGET' named entity 'PROBE' named entity 'EPITOPE' named entity 'THROMBIN' named entity 'INTACT' named entity 'PATIENTS' named entity 'CERVICAL CANCER' named entity 'OSTEOPONTIN' named entity 'FRAGMENTS' named entity 'ABSENT' named entity 'THROMBIN' named entity 'MAB' named entity 'SUPPORTED' named entity 'COULD BE' named entity '28147' named entity 'RESULTS' named entity 'PROTEIN TRUNCATION' named entity 'INDIVIDUALS' named entity 'HIGHER' named entity 'OPN' named entity '28614' named entity 'CAPTURE'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software